Diamedica Doses First Patient in DM199 Preeclampsia Trial
DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, has initiated its Phase 2 investigator-sponsored trial for DM199, a potential preeclampsia...
GenSight Submits Lumevoq® Dossier to ANSM for Early Access Program Restart
GenSight Biologics has submitted an updated regulatory file for its LUMEVOQ® gene therapy to the French medicines safety agency...
Carmat’s Aeson® Artificial Heart Revolutionizes Transplants in Europe
CARMAT’s Aeson® artificial heart has seen increased adoption as a European bridge-to-transplant solution. By the end of October 2024,...
Quince Therapeutics Unveils Promising Attest Trial Safety Data at CNS Meeting
Quince Therapeutics, a late-stage biotechnology company, announced safety data from its Phase 3 ATTeST clinical trial at the 53rd...
Neurogene Reports Positive Interim Data from NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
Neurogene Inc. announced positive interim clinical data from its Phase 1/2 open-label trial of NGN-401 gene therapy for Rett...
Tezspire Meets Co-primary Endpoints in Phase 3 WAYPOINT Trial
A Phase III trial, WAYPOINT, has yielded positive results for AstraZeneca and Amgen’s TEZSPIRE (tezepelumab) in treating chronic rhinosinusitis...
Sarepta Q3 2024: Financial Results & Developments
Sarepta Therapeutics reported strong third-quarter 2024 financial results, marked by a significant revenue increase and positive net income. Net...
Janux Therapeutics Q3 2024 Financial Results & Highlights
Janux Therapeutics, a clinical-stage biopharmaceutical company, recently announced its third-quarter 2024 financial results and provided a business update. The...
Gilead Sciences Announces Strong Q3 2024 Results
Gilead Sciences reported third-quarter solid 2024 financial results, with a 7% year-over-year increase in total product sales, reaching $7.5...
Viridian Therapeutics Grants Inducement Awards
Viridian Therapeutics, a Nasdaq-listed biopharmaceutical company (VRDN), granted stock options to six new employees on November 1, 2024. These...